# Marengo Therapeutics

Source: https://onco.cc/companies/marengo-therapeutics/  
OnCo record `marengo-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Marengo Therapeutics, of Cambridge, Massachusetts, makes antibodies that bind part of the T-cell receptor to activate selected subsets of a patient's T cells. Its lead, invikafusp alfa, is in trials in tumours with a high mutational burden that have stopped responding to checkpoint drugs, and with an antibody-drug conjugate in breast cancer.

## Summary

Marengo Therapeutics is a clinical-stage Cambridge, Massachusetts company developing TCR-targeting antibodies that selectively modulate T-cell subsets. Its STAR platform (precision T-cell agonist) bispecifics include invikafusp alfa, in clinical development as monotherapy in immune checkpoint blockade-resistant, tumour mutational burden-high tumours (START-001) and in an antibody-drug conjugate combination in breast cancer (START-002), plus partnered STAR programmes. The TriSTAR platform (precision T-cell engager) includes TriSTAR0701 targeting Nectin-4 for bladder and other cancers and several partnered candidates, and the MSTAR platform (precision T-cell depleter) is aimed at autoimmune disease. Marengo's news page lists Apple Tree Partners as lead investor. Financing amounts and series were not stated on fetched pages.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Cambridge, MA
- Type: biotech
- Website: https://marengotx.com/

## Notes

- No funding round sourced; press releases on the site are loaded client-side and could not be read.

## Sources

- Official website: https://marengotx.com/
- Pipeline: https://marengotx.com/pipeline/
- News and investors: https://marengotx.com/news-investors/

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [Nectin-4](https://onco.cc/targets/nectin4/)
- trials: [A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct05592626/), [A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct06827613/)

---
JSON: https://onco.cc/api/v1/entities/marengo-therapeutics.json